Trial reportThe British journal of ophthalmology2007
Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial.
Trial report in The British journal of ophthalmology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Antibiotics for trachoma.The Cochrane database of systematic reviews · 2019Pooled it
- Pooled it
- Epidemiology and control of trachoma: systematic review.Tropical medicine & international health : TM & IH · 2010Pooled it
- Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis.The British journal of ophthalmology · 2014Trial
- Adverse events after mass azithromycin treatments for trachoma in Ethiopia.The American journal of tropical medicine and hygiene · 2011Trial
- Comparison of Methods for Assessing Chlamydia trachomatis Transmission Intensity: A Systematic Review.The American journal of tropical medicine and hygiene · 2026Article
- Neglected tropical diseases in Republic of Guinea: disease endemicity, case burden and the road towards the 2030 target.International health · 2023Review
- Prevalence of trachoma and associated factors in the rural area of the department of Vaupés, Colombia.PloS one · 2020Article
- Effectiveness and safety of azithromycin 1.5% eye drops for mass treatment of active trachoma in a highly endemic district in Cameroon.BMJ open ophthalmology · 2020Article
- Ocular Chlamydia trachomatis infection: elimination with mass drug administration.Expert review of anti-infective therapy · 2019Review
- Self-Reported Side Effects following Mass Administration of Azithromycin to Eliminate Trachoma in Amhara, Ethiopia: Results from a Region-Wide Population-Based Survey.The American journal of tropical medicine and hygiene · 2019Article
- The limits of medical interventions for the elimination of preventable blindness.Tropical medicine and health · 2014Article
- Azithromycin: assessment of intrinsic cytotoxic effects on corneal epithelial cell cultures.Clinical ophthalmology (Auckland, N.Z.) · 2013Article
- Trachoma: an update on prevention, diagnosis, and treatment.Current opinion in ophthalmology · 2012Review
- Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis.Drugs · 2012Review
- Review of Azithromycin Ophthalmic 1% Solution (AzaSite(®)) for the Treatment of Ocular Infections.Ophthalmology and eye diseases · 2012Article
- A European perspective on topical ophthalmic antibiotics: current and evolving options.Ophthalmology and eye diseases · 2011Article
- Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite) solution in the treatment of ocular infections.Clinical ophthalmology (Auckland, N.Z.) · 2011Article
- Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops.PLoS neglected tropical diseases · 2010Article
- Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness.The British journal of ophthalmology · 2010Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsEfficacy and safety of a short-duration treatment of azithromycin 1.5% eye drops versus oral azithromycin to treat active trachoma.
methodsRandomised, controlled, double-masked, double-dummy, non-inferiority explanatory study including 670 children from Guinea Conakry and Pakistan if: 1-10 years old; active trachoma (TF+TI0 or TF+TI+ on simplified World Health Organisation (WHO) scale). Three groups received either: azithromycin 1.5% eye drops twice daily for 2 days, for 3 days or azithromycin single 20 mg/kg oral dose. Patients' contacts were treated whenever possible. Clinical evaluation was performed using a binocular loupe. Primary efficacy variable was the cure (no active trachoma (TF0)) at day 60. Non-inferiority margin for difference between cure rates was 10%.
resultsCure rate in per protocol set was as follows: 93.0%, 96.3% and 96.6% in 2-day group 3-day group, and oral treatment group, respectively. Azithromycin 1.5% groups were non-inferior to oral azithromycin. The intend to treat (ITT) analysis supported the results. Clinical re-emergence rate was low: 4.2%. Ocular tolerance was similar for all groups. No treatment related adverse events were reported. Logistic regression analyses found prognostic factors such as: country (p<0.001) and trachoma severity (p = 0.003).
conclusionsIn active trachoma, azithromycin eye drops twice daily for 2 or 3 days are as efficient as the WHO's reference treatment and represent an innovative alternative to oral azithromycin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.